跳至主要内容
临床试验/NCT00255749
NCT00255749已完成2 期

Assessment of Early and Standard Intervention With Procrit® (Epoetin Alfa) 120,000 Units Once Every Three Weeks (Q3W) in Patients With Cancer Receiving Chemotherapy

Jonsson Comprehensive Cancer Center2 个研究点 分布在 1 个国家目标入组 89 人开始时间: 2005年8月最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
89
试验地点
2
主要终点
Efficacy

研究概览

简要总结

RATIONALE: Epoetin alfa may cause the body to make more red blood cells. It is used to treat anemia caused by cancer and chemotherapy.

PURPOSE: This randomized phase II trial is studying how well epoetin alfa works in treating patients with anemia who are undergoing chemotherapy for cancer.

详细描述

OBJECTIVES:

Primary

  • Determine the efficacy, in terms of maintenance of target hemoglobin and hematocrit levels, of interval dosing with epoetin alfa in patients with anemia undergoing chemotherapy for nonmyeloid cancer.
  • Determine the safety of this drug in these patients.

Secondary

  • Determine the quality of life of patients treated with this drug.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Efficacy

时间窗: 7 weeks

Safety

时间窗: 7 weeks

次要结局

  • Quality of life(7 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验